RxDoctor Payments Data

Patrick Doherty, MD

Neurological Surgery · New London, CTNPI 1578620282

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (40.9%), royalties or licence payments and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Royal Biologics, Inc. at 33.4% of the total. Reporting peaked in 2019 at $21,259 and has fallen 60.0% since, to $8,511 in 2025.

$71,840in general payments, 2019–2025

Across 182 payments — averaging $394.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Royal Biologics, Inc.$24K
  • Spineart SA$16K
  • Globus Medical$14K
  • Kuros Biosciences USA, Inc$7K
  • Atlas Spine, Inc.$6K
  • Spineart USA Inc$649
  • plus $4K from 20 others
$40,213in research payments, 2019–2025

Across 11 payments — averaging $3655.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$40K

What the payments were for

  • Royalty or licence$19,86828%
  • Consulting fees$29,34841%
  • Speaking & faculty fees$5001%
  • Travel & lodging$13,53619%
  • Food & beverage$8,58812%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,840 in reported general payments places this provider in the 85th percentile of 94 neurological surgery providers in Connecticut.

See all neurological surgery providers in Connecticut

Medicare billing

Part B allowed, 2024
$190,505
Medicare patients
183
Services billed
535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclobenzaprine Hcl107$817
Celecoxib23$671
Pregabalin28$619
Oxycodone Hcl103$581
Diclofenac Sodium18$564
Gabapentin45$477
Baclofen26$382
Tizanidine Hcl19$373
Methocarbamol23$257
Methylprednisolone34$254
Mupirocin28$238
Tramadol Hcl30$141
Meloxicam14$36

Paid to pharmacies, not to this prescriber.

Other neurological surgery in New London

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →